Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 3/20 | 0.48 |
| ▸ | PADI1 | Q9ULC6 | 3/20 | 0.48 |
| ▸ | PADI4 | Q9UM07 | 3/20 | 0.48 |
| ▸ | PADI2 | Q9Y2J8 | 3/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.48 |
| ▸ | PADI3 | Q9ULW8 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858324 | 0.95 | LMNA (0.54) | LMNATDP1HSD17B10PDE4APADI1 | |
| SCHEMBL5857603 | 0.88 | CA2 (0.55) | LMNATDP1HSD17B10HPGD | |
| SCHEMBL5857789 | 0.87 | PDE4A (0.45) | LMNATDP1HSD17B10PDE4APADI1 | |
| SCHEMBL9830868 | 0.87 | CA2 (0.53) | LMNATDP1HSD17B10HDAC4HDAC3 | |
| SCHEMBL12809901 | 0.85 | PRSS1 (0.56) | LMNATDP1HSD17B10PDE4APADI1 | |
| SCHEMBL11545905 | 0.84 | NAAA (0.57) | PDE4APADI1PADI4PADI2PDE4B | |
| SCHEMBL5856479 | 0.84 | KMT2A (0.46) | LMNATDP1HSD17B10ADAMTS4ADAMTS5 | |
| SCHEMBL5855561 | 0.83 | CA2 (0.56) | LMNATDP1HSD17B10HPGD | |
| SCHEMBL16155818 | 0.83 | CA2 (0.56) | LMNATDP1HSD17B10HPGD | |
| SCHEMBL16149959 | 0.83 | CA2 (0.56) | LMNATDP1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| CN-1238347-C | Heterocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2006-01-25 | — | — | CN | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| CN-1430612-A | Hete rocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2003-07-16 | — | — | CN | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | LMNA 606/4885TDP1 2093/4885HSD17B10 35/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | LMNA 601/4885TDP1 1488/4885HSD17B10 37/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | LMNA 636/4885TDP1 1422/4885HSD17B10 39/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | LMNA 636/4885TDP1 1422/4885HSD17B10 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.